HALOZYME THERAPEUTICS, INC. : LEERINK PARTNERS CUTS TO MARKET PERFORM FROM OUTPERFORM; RAISES TARGET PRICE TO $117.00 FROM $110.00

Reuters · 2d ago

Please log in to view news